Fred Mermelstein

Co-Founder, CEO & President at Raqia Therapeutics

Fred has founded numerous biotech companies with successful exits, including Pear Tree Pharmaceuticals, Javelin Pharmaceuticals, and PolaRx Biopharmaceuticals. He is also a founder and Chairman of the Board of SanaRx Biotherapeutics and Courage Therapeutics and serves as a Director for NextRNA. Fred is also an experienced investor, having served several roles in biotech venture capital and private equity. Fred received a joint Ph.D. in Pharmacology and Toxicology from Rutgers University and UMDNJ-RWJ.


Org chart


Teams


Offices

This person is not in any offices


Raqia Therapeutics

Raqia Therapeutics is an exciting startup company developing a transformative chimeric antigen receptor (CAR) technology for immunotherapy. At Raqia Therapeutics, they are motivated to bring life-changing therapy to patients with cancer.


Industries

Employees

1-10

Links